Bladder cancer is the most common tumor in the urinary system, with approximately 420,000
new cases and 160,000 deaths per year. The European Organization for Research and …

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab),
neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination …

PURPOSE To evaluate the safety and efficacy of gemcitabine and cisplatin in combination
with the immune checkpoint inhibitor pembrolizumab as neoadjuvant therapy before radical …

Background For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available
for clinical use to predict response to neoadjuvant chemotherapy. Objective To investigate …

Simple Summary Although it is one disease, cancer of the urinary bladder occurs in several
molecular subtypes that can be identified by laboratory tests. Tumors of advanced stages …

Background In the PURE-01 study, pembrolizumab was given preoperatively before radical
cystectomy in clinical T2-4aN0M0 patients. An accurate clinical response assessment may …

Objective To describe the natural history of untreated muscle‐invasive bladder cancer
(MIBC) and compare the oncological outcomes of treated and untreated patients. Patients …

Background Neoadjuvant chemotherapy (NAC) is the standard of care in muscle-invasive
bladder cancer (MIBC). However, treatment is intense, and the overall benefit is small …

Muscle-invasive bladder cancer (MIBC) is an aggressive disease requiring active
management. Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is …

Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the
standard treatment for patients with muscle-invasive bladder cancer (MIBC). However, the …